Kiniksa Pharmaceuticals Reports Strong Earnings, Driving Stock Up 24%

Kiniksa Pharmaceuticals (NASDAQ: KNSA) saw its stock rise nearly 24% after reporting first-quarter 2026 earnings that exceeded analyst expectations. Revenue from its drug Arcalyst increased to $214 million, and net income more than doubled to $22.6 million. The company also raised its sales forecast for Arcalyst due to its recent approval for pericarditis.

By Eric Volkman, The Motley Fool Wed, April 29, 2026 at 2:30 AM GMT+3 3 min read · Yahoo Finance · April 28, 2026, 23:30 UTC

Tickers: $KNSA

Topics: Arcalyst Biotech Earnings Revenue Growth Stock Price Movement

Read the full article at Yahoo Finance

More World news

Apple to Update HomeView Software Following Feedback on Voice Command Limitations The Verge · November 12, 2026, 16:53 UTC
Endeavour Mining Shares Drop Following Production Warning at Mana Gold Mine Seeking Alpha · November 12, 2026, 16:48 UTC
Stellantis CEO Warns of Multi-Billion Euro Impact from Chip Shortages and Raw Material Costs Seeking Alpha · November 12, 2026, 16:44 UTC
UBS Upgrades Rivian to Buy Rating Amid R2 Potential Motley Fool · November 12, 2026, 16:45 UTC
Stifel Downgrades EVgo to Hold Amid Weakening Growth Outlook Seeking Alpha · November 12, 2026, 16:41 UTC
Rowan Digital Infrastructure Secures Over $1.5 Billion in New Financing Seeking Alpha · November 12, 2026, 16:42 UTC
CAE Reports Q2 2027 Results with Increased EPS Guidance and Strong Defense Growth Motley Fool · November 12, 2026, 16:39 UTC
Alvotech Reports Q3 2026 Financial Results Amid Manufacturing Recovery Motley Fool · November 12, 2026, 16:39 UTC
Jacobs Solutions Declares Quarterly Dividend of $0.36 Per Share Seeking Alpha · November 12, 2026, 16:39 UTC
SOLV Energy Raises Revenue Guidance Following Record Q3 Project Execution Seeking Alpha · November 12, 2026, 16:40 UTC